• Healthy Extracts Inc. recently declared its 2020 Q4 results showing an exponential revenue increase of 71% from last year
• The company’s proprietary Fuel4Thought(TM) Brain Booster product is undergoing clinical testing, and is slated for release in Q2
• Healthy Extracts, Inc.(TM) officially changed its name from Grey Cloak Tech Inc. on March 1, 2020

Healthy Extracts (OTCQB: HYEX), is a leading researcher and manufacturer of plant-based formulations whose objective is to offer a better lifestyle through superior heart and brain health technology. The company is focused on strengthening and expanding its market reach through its science-based wholly-owned subsidiaries BergaMet North America (BergaMet NA) and Ultimate Brain Nutrients (“UBN”). In a recent announcement by Healthy Extracts, the company revealed its year-end financial reports for the year ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377. Healthy Extracts attributes its revenue boom to its adaptation of selling health-nutrition products (https://ibn.fm/Z9cjW). There has been a worldwide increase in health concerns due to the COVID-19 pandemic, greenhouse gas emissions, and the increased environmental pressure due to animal rearing. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027. These results are supplemented by a 2020 study by the Yale Program on Climate Change Communication, whose findings suggest that despite only 4% of the population being vegans or vegetarians, 94% of Americans are inclined towards plant-based foods (https://ibn.fm/RIx6b). Kevin Duke Pitts, Director, President, and CEO of HYEX stated that Healthy Extracts officially changed its name from Grey Cloak Tech Inc. on March 1, 2020, to reflect its business line of operations. The company currently operates through its two subsidiaries, having shut down Eqova in 2019. Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary product formulations derived from the rare Citrus Bergamot Superfruit(TM) (“bergamot”) native to Southern Italy. With its natural source of various antioxidant polyphenols, Bergamot has anti-inflammatory properties, reduces cholesterol, and is being touted as an effective heart health supplement. UBN develops unique, plant-based superior proprietary neuro-brain solutions that enhance the brain’s overall health. Some other business highlights for 2020 include a full reporting and upgrade to the OTCQB, the acquisition of Ultimate Brain Nutrients, and the introduction of two key products: BergaMetNA Clinical Immune and BergaMetnNA HerHeart. Clinical testings are ongoing in full-swing on the company’s proprietary Fuel4Thought Brain Booster product, which is slated for release in Q2 (https://ibn.fm/QzzJ8). For more information, visit the company’s website at www.HealthyExtractsInc.com. NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

• For more than a year, the novel coronavirus has upended society’s day-in, day-out routines and has contributed to a sense of unease nationally and worldwide
• Wide vaccine rollout and declining virus infection rates are cause for optimism about the nation’s response to COVID, but daily routines have yet to return to “normal”
• Two recent back-to-back mass-casualty shooting incidents have further threatened society’s stability and have revived debates over how to stem large-scale public violence
• Autonomous security robot (“ASR”) developer Knightscope is intent on helping to restore normalcy and greater calm through the deployment of unarmed ASR sentries that can patrol perimeters and discourage crime 24/7 without fear of falling ill or victim to violence
• A Las Vegas newspaper recently reported on a Knightscope client’s happy response to declining crime rates at an apartment complex following the ASR’s deployment last fall

History may come to regard the present years as “The COVID Era,” considering the sociological upheaval that has taken place worldwide as a result of the pandemic now stretching into its second year. The novel virus has made its presence known in all strata of society and although aggressive new vaccine rollout and declining rates of infection in many areas are generating a newfound sense of optimism, most people may yet find it difficult to remember the ease with which we once we enjoyed some basic entertainments like going to the movie theater or the city swimming pool. That difficulty was evident in the recent announcement by The Walt Disney Co. that it will delay its long-awaited superhero film “Black Widow” for a third time, but commit to finally securing its release by simultaneously making it available to home viewers on its streaming Disney+ service — a decision that dealt a blow to movie theaters hoping to begin their financial recovery from pandemic closures during the coming summer (https://ibn.fm/1WuGA). While the health crisis and vaccination efforts continue to capture primary placement in national media headlines, the idea of revolutionizing the private security guard industry may not appear as imaginative as efforts to return daily activities to “normal” but the autonomous security robot (“ASR”) innovators at Knightscope regard their mission as part and parcel of efforts to restore the well-being of the American people. “A violent crime occurs every four seconds and a property crime every 25 seconds,” Knightscope founder and CEO William Santana Li says in a recent company video biopic (https://ibn.fm/RqK1J). “Additionally the mass shooting violence across the country is not acceptable. … I don’t believe the founders of our great country ever expected that we would build a society where going to school, going to work, going shopping or to a movie literally came with a risk of being shot or killed. Crime has more than a trillion-dollar negative economic impact on the U.S. every single year.” Two mass-casualty shootings, one in Colorado and another in Georgia in less than a week’s time, are reminders that such violence and the debate over how to stave it off continue (https://ibn.fm/JPBtw). Knightscope’s response solution comes in the form of autonomous sentry robots that provide property perimeter vigilance 24 hours a day, 365 days a year. The ASRs are not weaponized defense machines like modern-day sci-fi Robocops, but they are uniquely capable of perceiving, recording and transmitting information to security personnel overseers and law enforcement while also allowing the security managers to speak immediately and directly to anyone in the ASR’s vicinity. That information may include streaming live video from a 360-degree perspective, visualizing dark and unseen areas with heat-sensing and thermal-imaging cameras, monitoring communications frequencies, and using AI to recognize targets of specific interest. One recent testimonial of the security robots’ potential to reduce crime through simple vigilance was reported this month by the Las Vegas Review-Journal, which noted that a crime-ridden apartment complex has become “a quieter, more peaceful place to live” since a Knightscope ASR was deployed there last fall. An officer with the Las Vegas Metropolitan Police Department observed the 1,129-unit apartment complex had been in the top three for 911 calls in the area, but now is no longer in the top 10, and the complex’s manager stated the ASR has deterred a lot of crime and vandalism (https://ibn.fm/Bv49z). Knightscope’s outreach team works to help ensure clients are trained in how to use the ASRs and can integrate them seamlessly into daily activity at the client property through “Post Orders” (https://ibn.fm/zTXKn). In any type of private security operation, training remains a critical requirement for ensuring the highest possible quality outcome, but unfortunately the need for ongoing, purposeful training of human security personnel may often be overlooked throughout the industry at large (https://ibn.fm/yJufp). “Long-term, I dream of building a $30 billion equivalent to a defense contractor,” Santana Li said. “Except (with a) focus on helping the U.S. Department of Homeland Security and the U.S. Department of Justice better secure our country with a wide-ranging portfolio of new ground-breaking technologies. I think it is possible.” For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy
• Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021
• The company is continuing its pre-clinical work on WP1244 during 2021 and 2022
• CNS Pharmaceuticals participated in two virtual conferences during March, spreading awareness about Berubicin and the GBM indicator

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced multiple value-driving milestones for its lead drug candidate Berubicin, a novel therapy targeting glioblastoma multiforme (“GBM”), as well as for its other drug candidate, WP1244, which targets several types of cancer (https://ibn.fm/y1XfB).

Glioblastoma Multiforme (“GBM”) is one of the most aggressive and deadly treatment-resistant cancers of the brain. GBM can affect a patient’s cognition, mood, behavior, and organ function. After diagnosis, the average life expectancy is 12-18 months resulting in close to 10,000 deaths annually in the United States. Every year, more than 13,000 new cases are diagnosed, making GBM 48% of all primary malignant brain tumors (https://ibn.fm/Z27t2).

Berubicin, one of two lead programs initially developed by Dr. Waldemar Priebe, a Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain. Berubicin is currently entering a potentially pivotal Phase 2 study for GBM treatment commencing around the end of Q1 2021. Two grant-funded studies are also scheduled to commence in Poland through WPD Pharmaceuticals, a sub-licensee partner of CNS Pharmaceuticals. The Phase 2 adult trial for GBM is expected to commence during Q2 2021 and the first-ever pediatric trial of Berubicin for malignant gliomas is expected to commence during H2 2021.

In its updated investor presentation, CNS Pharmaceuticals outlines several value-driving milestones for Berubicin that are expected to take place during 2021. These milestones include:

1. Entering three clinical trials during 2021, including the potentially pivotal Phase 2 study commencing around the end of Q1 2021
2. The interim data from WPD’s trial in Poland of Berubicin in adult GBM is expected during Q4 2021-Q1 2022
3. Multiple growth opportunities exist with the WP1244 program and the expansion into other indications

CNS Pharmaceuticals’ other drug candidate currently in development, WP1244, is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation. The current target indications for WP1244 include brain cancers, pancreatic cancers, ovarian cancers, and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity. There is currently a sponsored research agreement between CNS Pharmaceuticals and The University of Texas MD Anderson Cancer Center for this drug candidate. Pre-clinical work on WP1244 will continue during 2021 and 2022.

Additionally, there is discussion of expanding Berubicin into other cancer treatment fields. The indications that are being explored include:

• Primary Brain Tumors
  • Relapsed High-Grade Gliomas – estimated population 15,000
• Brain Metastases-Combination with Radiation Therapy
  • Small Cell Lung Cancer – estimated population 56,500
  • Non-Small Cell Lung Cancer – estimated population 56,000
  • Metastatic Breast Cancer – estimated population 45,000
• CNS Lymphoma
  • Second line treatment after Methotrexate failure – estimated population 1,200

CNS Pharmaceuticals’ latest investor presentation also outlines several financial highlights. Notable achievements financially include the November 7, 2019, $9.8 million IPO, a $14 million cash balance as of December 31, 2020, and around 23.9 million shares outstanding. Based on a 10-day average of March 12, 2021, the company has a market cap around $58 million with an average volume of around 347,000.

To further advance and raise awareness of its novel therapies, CNS Pharmaceuticals attended two prominent virtual conferences in March 2021: H.C. Wainwright Global Life Sciences Conference (March 9-10) and was the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC (March 17-18). On the sidelines of the H.C. Wainwright Global Life Sciences Conference, CEO John Climaco also had the opportunity to participate in one-on-one meetings with qualified investors, while at the Emerging Growth Virtual Conference he also participated in a live glioblastoma panel discussion.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Pac Roots Cannabis recently revealed it had commenced trading on the Frankfurt Stock Exchange under symbol “4XM”
• German listing will add on to company’s existing listings on U.S. OTC market, Canadian Securities Exchange
• Pac Roots’ geographically diverse capital markets presence will allow it to cater to broader, more diverse investor audience
• Europe’s legal cannabis market expected to swell to market value of $37.1 billion by 2027

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canada-based cannabis company dedicated towards producing premium-quality strains and products by leveraging a genetics-focused approach, announced that as of March 18, 2021, the company had commenced trading in Europe on the Frankfurt Stock Exchange under the symbol “4XM” (https://ibn.fm/AAJHd). Pac Roots will continue to be simultaneously quoted on OTC Markets under the symbol “PACRF” as well as trade on the Canadian Securities Exchange under the trading symbol “PACR.” The Frankfurt Stock Exchange listing will be a key avenue for Pac Roots to further broaden and diversify its shareholder base throughout the European Region as well as the United States. The Frankfurt Stock Exchange ranks as the largest of Germany’s seven equity bourses and as the world’s twelfth largest stock exchange by market capitalization. Furthermore, it caters to a diverse investor audience – of the approximately 200 market participants currently active on the market, approximately 50% originate from countries other than Germany. “With the cannabis industry gaining momentum in Europe, this additional listing will help increase our visibility and open doors to new investors as well as enable exciting business opportunities,” said Pac Roots President and CEO Patrick Elliott. Cannabis consumption has been increasingly decriminalized in the United States, with 34 individual states in the U.S granting consumers access to medical or recreational cannabis; however, the legalization process in Europe has lagged some way behind. European countries are scrambling to update their regulations in response to ever-increasing pressure to ease restrictions and provide an outlet for a profitable industry which is rapidly globalizing. France and Germany are currently carrying out clinical trials on the use of medical cannabis, whereas the Netherlands and Switzerland are expected to implement recreational programs by the end of the year (https://ibn.fm/jxUlU). In what may be the the biggest indication of the region’s commercial potential, Curaleaf Holdings Inc.  recently agreed to purchase privately held Emmac Life Sciences Ltd, Europe’s largest independent medical cannabis company for about $285 million, gaining access to the European Union’s medical marijuana and CBD consumer markets. The deal marked the latest iteration within the European cannabis industry’s cross-border M&A activity, with previous deals seeing the likes of Israel’s Intercure Ltd agreeing to be purchased by a U.S. SPAC and Canadian cannabis company Tilray Inc., touting its European growth plans as part of its merger with Aphria Inc. Europe’s cannabis market was recently valued at approximately $3.49 billion as of the end of 2019 (https://ibn.fm/3OASf), a mere fraction of the estimated $33.1 billion value of the legal marijuana industry in the United States this year. However, the market is estimated to swell to over $37 billion by 2027 as the pace of legalization picks up in the EU’s different member states, placing Pac Roots Cannabis in an ideal position to benefit from increased European capital market interest within the sector. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical company
• Sale to Germany expected to pave way for additional supply agreements throughout Europe
• Company orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulation
• PULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports

With a focus on the cannabis, hemp, functional mushrooms and rapidly emerging psychedelic sectors, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company, is steadily increasing its market share through the achievement of several important milestones. Along with the Company’s first shipment of functional mushrooms for its e-commerce portal, Pure Extracts has expanded into the European Union (“EU”) through an initial sale of cannabis oil extracts to a German pharmaceutical company.

Germany is one of the largest and most innovative economic markets in Europe (https://ibn.fm/ivhQF). Pure Extracts’ management expects the initial sale will lead to more long-term supply agreements and additional export opportunities to other EU countries where the Company’s products can be legally sold. With a focus on the medical cannabis sector, the Company purchases Canadian-grown, EU-GMP-certified, dry cannabis flower and extracts it into 85% pure THC distillate and 70% pure THC full spectrum oil (“FSO”) that can be processed into an ultra-pure form of THC for medicinal purposes.

“It is gratifying to have had our concentrates selected by a German pharmaceutical company for use in their medical products,” said Pure Extracts CEO Ben Nikolaevsky (https://ibn.fm/Kpdwa). “We are excited about the entire European market opportunity for our extracts.”

Along with prospective domestic and international supplier agreements, Pure Extracts will also sell its functional mushroom wellness products online through its direct-to-consumer e-commerce portal. The Company recently ordered its first shipment of functional mushrooms from its British Columbia co-packer and plans to have Reishi and Maitake formulations available in April followed by the addition of a Lion’s Mane formulation by the end of Q2 with expected gross sales of $15,000 per month for each product.

“We are excited to be ordering the first Pure Mushrooms products to launch our direct-to-consumer, online store,” said Nikolaevsky (https://ibn.fm/Vjp9a). “The functional mushroom wellness market is experiencing robust sales as many consumers are trying to boost their immune systems in light of the COVID-19 pandemic. As we build out our mushroom extraction facility, we plan to bring more products to market.”

Pure Extracts is now trading on the Canadian Securities Exchange under the symbol “PULL”, the Frankfurt Stock Exchange under “A2QJAJ”, and the U.S. OTC market under “PRXTF”. The Company’s state-of-the-art newly constructed processing facility is built to EU GMP standards with the aim of exporting products globally to locations where their sale and consumption are permitted. As the market for functional and medicinal psychedelic products gains traction worldwide, Pure Extracts is poised to gain significant market share through its commitment to developing first-in-class extracts for the rapidly growing functional and medicinal plant-based medical industry.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems
• Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research
• Knowledge encapsulated by Helomics AI is “gold dust,” says chief innovation officer

Data, AI and biology come together at Helomics in a way that promises exciting things for the future, according to  Mark Collins, PhD and chief technical officer at the company, which is a subsidiary of Predictive Oncology (NASDAQ: POAI) (https://ibn.fm/ms1hL). Collins was a guest speaker on a DojoLIVE! podcast titled “Can We Cure Cancer with Artificial Intelligence?” where he discussed what Helomics is bringing to the table in the field of cancer research.

“At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you might get if you were diagnosed with cancer,” he said. “We have a massive collection of data that goes along with that drug response — over 150,000 tumors, which is a huge data set. And then again we have AI. And it’s that convergence of AI, the big data if you will, and the biology that means we’re able to test drugs on living tumor tissue rather than some artificial system that is really what’s driving what we do.”

During the podcast, Collins explained what makes Helomics distinctive.

“We don’t just look at one aspect of the tumor,” he said. “We look at multiple, as it were, measurements of that tumor. How it responds to drugs, what it looks like, what mutations it has in its DNA, how different genes are expressed, so it’s what we call a multi-omics approach. . . . Cancer is so complex, the human body is so complex, it’s not going to be just down to one thing that’s driving how the tumor or the patient responds to drugs.”

Collins pointed out that Helomics currently specializes in ovarian cancer. “We developed and have a validated clinical assay where we take a sample from the patient following surgery to remove the tumor,” he explained. “We grow that tumor in the lab, we test drugs on it, we look at different mutations in the tumor, and then we compare that with the data that we have in our database, and we feed that back to the oncologist to guide treatment.”

The company doesn’t make a recommendation or prescribe medication, but the information Helomics provides helps the clinician determine drug treatment. “This drug response profile that we can generate really moves the needle for patients,” Collins said. “And in our clinical validation studies we can show that if the clinician chooses the drug that was indicated by this drug response assay, that we can extend the disease-free period for about two and half times longer than if they didn’t follow that recommendation.”

While AI isn’t a part of this particular process at the moment, Collins says the expectation is that it soon will be. “We’re doing a study with a local hospital in ovarian cancer where we expect to be able to produce a predictive model that will predict what drug [the patient] should be on and what outcome you’ll have. Now we have to clinically validate that before we can use it to individualize treatment,” he continues, “so it will be a couple of years before the AI is making those kinds of clinical decisions. But because the AI has encapsulated all this knowledge about the tumor, that is gold dust. Pharma companies are becoming very interested in these kind of models that use real world data and can help them discover new therapies in a much more knowledge-driven way than they perhaps do at the moment.

“AI will also help us discover drugs in the not-too-distant future,” Collins concludes. “Faster because we do less experimentation, smarter because we use the machine learning. Coupling adaptive learning (a special kind of machine learning) together with our data allows us to decide which experiments to do, and then we do those experiments using the right biology which is our live tumor testing platform. Certainly, pharma companies that we’ve already talked to are beginning to see that this kind of union between simulation, AI, big data and relevant biology is really going to make a difference to our ability to make new medicines for cancer.”

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Mohawk Group Holdings Inc. has announced its Q4 and full-year 2020 results
• The Q4 Net Revenue Grew 61.9% Year-Over-Year to $41.5 Million from $25.6 million in Q4 2019
• The company’s full-year operating loss of $(34.8) million improved from $(54.3) million in 2019

Mohawk Group Holdings (NASDAQ: MWK) is a CPG (Consumer Packed Goods) platform concentrated on developing proprietary technology using data and artificial intelligence to operate and manage consumer product brands. AIMEE(R) (AI Mohawk E-commerce Engine) is the company’s next-generation E-commerce platform that employs the latest technologies to launch new CPG products and identify market opportunities. These CPG products constitute 12 brands in multiple categories ranging from kitchenware, consumer electronics, and home appliances to environmental appliances. The company recently announced its Q4 and Full-Year 2020 results, some major highlights are as below:

• Full-year net revenue grew by 62.3% year-over-year to $185.7 million, from $114.5 million in the full year of 2019. The fourth-quarter net revenue grew 61.9% to $41.5 million, from $25.6 million in the fourth quarter of 2019
• The full-year gross margin improved to 45.6% as compared to 39.4% in 2019. The fourth-quarter gross margin improved to 45.2% compared to 35.4% fourth quarter of 2019
• Full-year operating loss of $(34.8) million improved from $(54.3) million in 2019. Full-year operating loss includes $12.7 million of loss related to change in fair value of potential future performance-based earnouts from acquisitions and $22.7 million of non-cash stock compensation
• The company’s actual quarterly loss of $0.33 per share compares to a loss of $1.06 per share a year ago. These figures are adjusted for non-recurring items

The company’s detailed 2019 Q4 result reports are available at https://ibn.fm/bv7lh. The quarterly net revenue grew 61.9% year-over-year and although they are still operating at a net loss as they grow, their full-year operating loss showed significant improvement from 2019 (https://ibn.fm/gqIGD). For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• ISW Holdings adds two revolutionary POD5IVE datacenters, triples its cryptocurrency mining fleet
• Each new datacenter brings potential $2.9 million in annualized revenues
• ISWH firmly committed to strategic vision for cryptocurrency mining amid record-high margins and growing acceptance of cryptocurrency assets

ISW Holdings (OTC: ISWH), a diversified global portfolio company comprised of essential business lines focused on telehealth and cryptocurrency mining, recently boosted its active cryptocurrency mining fleet with additional POD5IVE datacenters (https://ibn.fm/7NaNw). Despite inevitable pandemic-related supply chain challenges, ISWH managed to add two POD5IVE datacenters. With these newly added units, the company effectively tripled its initial mining fleet; the company now operates three POD5IVE data center units, expected to significantly impact its financial fundamentals. ISWH’s Pod5 Cryptocurrency Mining Pod is a fully self-contained, high-PUE mining solution designed, assembled and installed in partnership with Bit5ive LLC at the Bit5ive 100 MW renewable energy cryptocurrency mining facility in Pennsylvania. The pod’s elegant, powerful and efficient design provides revolutionary dynamic plug-and-play operation that offers industry top-of-the-range 1.06 power usage effectiveness score. Self-managed and with virtually no maintenance requirements, this state-of-the-art datacenter pod is a unique cryptocurrency mining equipment solution. ISW Holdings began implementing a four-phase growth plan last year. Phase 1 and 2, which involved developing the design and establishing a supply chain to build its revolutionary Pod5 mining solution in partnership with Bit5ive, has been completed. Further advancement on the path towards robust growth continues with phase 3, which includes the mining launch, targeting revenue generation from participation in the Bit5ive Pennsylvania project and expanding the mining activities through additional Pod5 units. The final phase 4 will include further expansion in total mining capacity and initial sales of Pod5 units, with the support from the company’s Bit5ive partnership and the track record from phase 3 operations (https://ibn.fm/LolCG). The expansion phase involves assembling, equipping and powering up additional Pod5 units that can house 300 miners each. Every unit represents approximately $2.9 million in annualized revenue-generating opportunity from mining activities at current market prices. ISW Holdings’ strategic vision for its cryptocurrency segment is based on fundamental confidence in the long-term viability of cryptocurrency as store of value and platform for global commerce. Aligned with that vision, the company is committed to invest, expand and capitalize on its robust investments made from May of last year at a time when margins are at historical levels following further strength in the value of cryptocurrency assets. “As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in Bitcoin prices,” said ISW Holdings president and chairman Alonzo Pierce. Cryptocurrency assets have seen significant uphold from prominent corporate, financial and regulatory players over the past year. All of this contributes to the increasing mainstream acceptance of crypto-assets, putting the company in a strong position given its early investment in developing the Pod5 last year. Based in Nevada, ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early-growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. ISWH maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

Stabilis Solutions (OTCQX: SLNG) is a vertically integrated energy transition company that provides clean energy solutions including small-scale liquefied natural gas (“LNG”) and hydrogen production, distribution and fueling services to multiple end markets in North America. As one of the continent’s most experienced small-scale LNG providers, Stabilis has safely provided over 250 million gallons of LNG through more than 25,000 truck deliveries during its 16-year operating history in the industry.

While serving a host of diverse markets such as aerospace, mining, energy, utilities and pipelines, commercial, and high horsepower transportation, Stabilis delivers solutions for cheaper, cleaner fuel. Stabilis is poised for massive growth opportunities in Mexico, where the Company recently completed the largest distributed natural gas project in Mexican history. The Company has also expanded its project pipeline, resulting in a potential to yield more than $200 million in new projects over the next several years.

As a turnkey provider of clean production, storage, transportation and fueling system solutions for LNG and hydrogen across North America, Stabilis takes great pride in its mission to reduce harmful emissions and partner with renewable energy while offering cost-effective solutions that support growth without requiring subsidies. LNG is the cleanest fossil fuel, representing an excellent alternative to reduce greenhouse gas emissions and help combat global warming. Stabilis’ Enlightened Energy™ is the bridge to renewables desperately needed to shift to a cleaner economy.

To see the recorded presentation delivered at last week’s Investor Summit, visit www.Stabilis-Solutions.com.

• Sales have steadily surged at Splash Beverage from $112,003 for Q1 2020 to $1.24 million in Q4 for $2.98 million for all of 2020
• Bill Meissner, Peter McDonough joined Splash Beverage Group in 2020, bringing decades of executive blue chip experience
• Splash completed $6 million acquisition of Copa Di Vino in early January 2021, made several other growth deals that will continue to improve financial performance in 2021 and beyond

The beverage game is big business—whether it’s alcoholic or non-alcoholic drinks. Some famous actors have put the spirit world on full display in recent years, including George Clooney selling his Casamigos tequila brand for reportedly up to $1 billion (https://ibn.fm/6XGCi) and Ryan Reynolds exiting his Aviator gin brand for up to $610 million (https://ibn.fm/YIpIk). There’s a reason that Dwayne “The Rock” Johnson has jumped into the space with his own tequila and Snoop Dogg is peddling a gin line as well. The beverage sector is experiencing tremendous growth, and while these celebrity brands are receiving a lot of attention, there are dozens of other brands making headlines with massive exits.  Accelerating preexisting brands is the area of specialty for another up-and-comer in the space, Splash Beverage Group (OTCQB: SBEV). By diversifying into both alcoholic and non-alcoholic segments, the Fort Lauderdale, Florida-based company de-risks its future while benefiting from production, supply chain and distribution efficiencies. The company’s brands include TapouT Performance (a hydration and recovery sport drink and partner to World Wrestling Entertainment (NYSE: WWE), SALT Naturally Flavored Tequila, Pulpoloco Sangria and Copa Di Vino wine. Copa Di Vino, “born” on Shark Tank, a leading producer of premium “wine by the glass” in the U.S., is Splash’s latest acquisition, capping a strong 2020 as detailed in the company’s recent 10-K annual report filed with the Securities and Exchange Commission (https://ibn.fm/3wtFZ). The year was transformational for Splash, including a merger in March that brought the company public followed by a ticker change to “SBEV” in July. Splash also made a few key leadership moves in 2020. Bill Meissner joined the team as chief marketing officer and sales president. Meissner has decades of experience in retail beverages, serving as president and/or CEO of Fuse, Sparkling Ice, Jones Soda, Sweet Leaf Tea and others. Additionally, Peter McDonough came on as an independent board member. McDonough has an unparalleled C.V. for sitting on the board of an upstart company, and he brings incomparable marketing experience to Splash. This type of leadership, along with the rest of the seasoned management at Splash, has helped to raise capital for expansion to the tune of $9.0 million through February 2021. Those funds can be used for organic growth and acquisitions, such as the Copa Di Vino buyout in December for $5.98 million. The measured growth initiatives are showing up in the financials, with sales starting in Q1 2020 at $112,003 and rising to $612,308 in Q2, then $1.01 million in Q3 and $1.24 million in Q4 for $2.98 million for 2020. Subsequent to the end of 2020, Splash has continued on a growth trajectory, not only completing the acquisition of Copa Di Vino, but also expanding distribution and sales of Salt Tequila via a deal with the U.S. Coast Guard and landing new distribution agreements for TapouT beverages throughout California, Florida and Alabama. In the upcoming quarters, investors will see how these new additions factor into the pattern of steady growth. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV